Metsera, the well-funded obesity biotech from Population Health Partners and ARCH Venture Partners, has unveiled its first clinical data just a few months after emerging …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Stacy is a preventive medicine and addiction medicine specialist. Since finishing residency, I have not practiced in a hospital or traditional outpatient office. My clinical
WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis from nonpartisan
The long-term beneficial effects of intermittent fasting (IF).